Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Devon Energy Corp (DVN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Devon Energy CorpTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Devon Energy Corp vs Recursion Pharmaceuticals Inc — how do they compare? Devon Energy Corp trades at $45.13 (market cap $49.90B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Devon Energy Corp is far larger — about 28× Recursion Pharmaceuticals Inc's market cap, and Devon Energy Corp pays a 2.82% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

DVNRXRX
Market Cap
$49.90B$1.78B
Sector
EnergyHealth
52-Week High
$52.07$6.79
52-Week Low
$31.74$2.84
Enterprise Value
$60.63B$1.30B
Dividend Yield
2.82%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Devon Energy Corp

No Aura AI signal available yet.

Recursion Pharmaceuticals Inc

RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.

Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Devon Energy Corp

Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.

Read more on DVN

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX